Format

Send to

Choose Destination
Rev Pneumol Clin. 2015 Feb;71(1):44-56. doi: 10.1016/j.pneumo.2014.11.004. Epub 2015 Feb 14.

[Immunotherapy in non-small cell lung cancer: inhibition of PD1/PDL1 pathway].

[Article in French]

Author information

1
Service de pneumologie et d'explorations fonctionnelles, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex, France; Centre d'étude des pathologies respiratoires, UMR 1100/EA6305, 37032 Tours, France; EA6305, université François-Rabelais de Tours, 37032 Tours, France. Electronic address: guillel@free.fr.
2
Service de pneumologie et d'explorations fonctionnelles, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex, France.
3
Centre d'étude des pathologies respiratoires, UMR 1100/EA6305, 37032 Tours, France; EA6305, université François-Rabelais de Tours, 37032 Tours, France.
4
Service de pneumologie et d'explorations fonctionnelles, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex, France; Centre d'étude des pathologies respiratoires, UMR 1100/EA6305, 37032 Tours, France; EA6305, université François-Rabelais de Tours, 37032 Tours, France.

Abstract

Despite recent advances in targeted therapy of non-small cell lung cancer (NSCLC), many patients do not benefit from these therapies. Inhibition of PD1/PDL1 is an interesting therapeutic target which restores the immune system against tumor cells. PD1 is located on lymphocytes and PDL1 on the antigen presenting cells. PD1 and PDL1 are co-inhibition molecules and their interaction results in immune tolerance against tumor cells. Anti-PD1 and anti-PDL1 antibodies have been developed to restore immune system in solid cancer including NSCLC. In phase I, studies assessing nivolumab, an anti-PD1 antibody, objective responses were observed in 13 to 18% of NSCLC patients failing previous treatment. The data obtained with anti-PDL1 antibodies is similar with objective responses ranging from 6 to 22%. The encouraging results of phase I/II studies must be confirmed in ongoing phase III studies. Anti-PD1 and anti-PDL1 antibodies exposed to new adverse events including auto-immune diseases whose support is not codified. Questions about treatment duration and criteria evaluation are not resolved. These treatments pave the way for immunomodulation in NSCLC treatment.

KEYWORDS:

Cancer bronchique non à petites cellules; Immunotherapie; Immunotherapy; Non-small cell lung cancer; Programmed death 1; Programmed death ligand 1

PMID:
25687821
DOI:
10.1016/j.pneumo.2014.11.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Masson (France)
Loading ...
Support Center